Abstract
Daratumumab (DARA) is a high-affinity human monoclonal antibody that specifically recognizes CD38. It has emerged as a breakthrough targeted therapy for multiple myeloma patients (pts). Monoclonal plasma cells in AL amyloidosis (AL) express CD38. We report here updated results of a prospective multi-center, phase 2 study of DARA in AL (NCT02816476).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
